News | June 17, 2009

MI Pharmaceutical Detects, Treats Prostate Tumor Cells

June 17, 2009 – Molecular Insight Pharmaceuticals Inc. presented clinical data on a radiolabeled, small-molecule molecular imaging pharmaceutical in development for diagnosis and staging of prostate cancer at the 2009 annual meeting of the Society of Nuclear Medicine (SNM) in Toronto.

Trofex, which targets prostate specific membrane antigen (PSMA), a protein highly expressed by prostate tumor cells, has the potential to both detect and, when labeled with a therapeutic isotope, to treat metastatic prostate cancer.

In 2008, Molecular Insight initiated clinical studies of Trofex in patients with documented prostate cancer and confirmed hormone refractory metastatic disease. Two internally developed Trofex compounds, MIP-1072 and MIP-1095, were evaluated for their capacity to visualize the disease and to define their pharmacokinetic profiles. Both agents rapidly detected metastatic prostate cancer lesions in soft tissues and bone, confirming that targeting the extracellular domain of PSMA is a viable approach for the molecular targeting of this cancer. The compounds were uniquely able to detect metastases within one to two hours after injection.

As John W. Babich, Ph.D., Executive Vice President, Chief Scientific Officer and President of Research and Development at Molecular Insight Pharmaceuticals, indicated, “Not only does this data demonstrate the capability to rapidly visualize bone metastasis and soft tissue lesions — that may be missed by conventional imaging techniques — imaging can be done in a single day, which is not possible with some of the products currently on the market for imaging recurrent metastatic disease.

Abstract Title:
Targeting Metastatic Prostate Cancer (PCa) in Patients using 123I-MIP 1072 & 123I-MIP 1095
Authors:
J.A. Barrett1; N.D. LaFrance1; R.E. Coleman2; S.J. Goldsmith3; J.B. Stubbs4; N. Petry2; S. Vallabhajosula3; K.P. Maresca1; F. Femia1; M. Stabin4; J.W. Babich1
1Molecular Insight Pharmaceuticals, Inc., Cambridge, MA, 2Duke University, Durham, NC ,3Cornell Medical Center, NY, NY 4, Radiation Dosimetry Systems, Inc, Palo Alto, CA

For more information: www.molecularinsight.com

Related Content

United Imaging Announces First U.S. Clinical Installation of uExplorer Total-body PET/CT
News | PET-CT | August 15, 2019
United Imaging announced that its uExplorer total-body positron emission tomography/computed tomography (PET/CT) system...
ASRT Supports Radiopharmaceutical Reimbursement Bill
News | Radiopharmaceuticals and Tracers | August 02, 2019
The American Society of Radiologic Technologists (ASRT) announced its support for House Resolution (HR) 3772, a measure...
International Multidisciplinary Group Publishes Recommendations for Personalized HCC Treatment With Y90 TheraSphere
News | Interventional Radiology | July 31, 2019
New consensus recommendations for personalized treatment for hepatocellular carcinoma (HCC) with BTG’s TheraSphere have...
NorthStar Medical Radioisotopes Awarded $30 Million by U.S. Department of Energy
News | Radiopharmaceuticals and Tracers | July 26, 2019
NorthStar Medical Radioisotopes LLC has been awarded $15 million in a cooperative agreement with the U.S. Department of...
NorthStar Medical Radioisotopes Completes Construction on Beloit, Wis. Molybdenum-99 Processing Facility
News | Radiopharmaceuticals and Tracers | July 16, 2019
NorthStar Medical Radioisotopes LLC  announced completion of construction on its 20,000-square-foot molybdenum-99 (Mo-...
Varian Purchasing Embolic Bead Assets from Boston Scientific
News | Interventional Radiology | July 03, 2019
Varian announced it has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable...
Bracco Imaging Acquires Blue Earth Diagnostics
News | Radiopharmaceuticals and Tracers | July 01, 2019
Bracco Imaging S.p.A. has signed a definitive agreement to acquire Blue Earth Diagnostics, a molecular imaging company...

Image courtesy of Philips Healthcare

Feature | Molecular Imaging | July 01, 2019 | By Sharvari Rale
Diagnostic procedures have always been a cornerstone of early prognosis and patient triaging.
DOSIsoft Receives FDA 510(k) Clearance for Planet Onco Dose Software
Technology | Information Technology | June 20, 2019
DOSIsoft announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Planet...
United Imaging Announces First U.S. Clinical Install of uMI 550 Digital PET/CT System
News | PET-CT | June 19, 2019
United Imaging announced the first U.S. clinical installation of the uMI 550 Digital positron emission tomography/...